Drug news
CHMP recommends Holocar for Limbal Stem Cell Deficiency- Chiesi
The CHMP has recommended granting a conditional marketing authorisation for the orphan medicine Holoclar from Chiesi for the treatment of moderate to severe Limbal Stem Cell Deficiency due to physical or chemical burns to the eyes in adults. Holoclar is the first advanced therapy medicine containing stem cells to be recommended for approval in the European Union.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.